EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation

Fuyuan Li, Yibin Mei, Qiongbi Wu, Xianjun Wu

Cardiology · 2024

DOI: 10.1159/000538551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology, 2024. Verfasst von Fuyuan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Mendelian Randomization Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertase 9. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with significant clinical implications. The potential influence of lipid-lowering therapies, specifically PCSK9 inhibitors (PCSK9i) and HMG-CoA reductase inhibitors (statins), on AF risk remains a topic of interest. This mendelian randomization (MR) study aimed to elucidate the causal relationship between genetically predicted inhibition of PCSK9 and HMG-CoA reductase and the risk of AF.

Methods

Utilizing publicly available, summary-level genome-wide association study data, we employed single-nucleotide polymorphisms associated with lower LDL-C levels as instruments for gene-simulated inhibition of PCSK9 and HMG-CoA reductase. Multiple MR techniques were applied to estimate the causal effects, and sensitivity analyses were conducted to validate the results.

Results

Genetically predicted inhibition of PCSK9 demonstrated a reduced risk of AF, with an odds ratio (OR) of 0.92 (95% CI: 0.85–0.99, p = 0.01) using the inverse variance-weighted (IVW) method. In contrast, the inhibition of HMG-CoA reductase did not exhibit a statistically significant association with AF risk (IVW: OR = 1.11, 95% CI: 1.00–1.22, p = 0.05).

Conclusion

Our MR study suggests that genetically predicted inhibition of PCSK9, but not HMG-CoA reductase, is associated with a lower risk of AF. These findings provide evidence for a causal protective effect of PCSK9i on AF and support the use of PCSK9i for AF prevention in patients with dyslipidemia. Further studies are needed to elucidate the mechanisms underlying the differential effects of PCSK9i and statins on AF and to confirm the clinical implications of our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationMendelian Randomization AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Polymorphism, Single NucleotideGenome-Wide Association StudyHumansPCSK9 InhibitorsCholesterol, LDLHydroxymethylglutaryl CoA Reductases

Stichwörter der Autor:innen

Atrial fibrillationDrug target mendelian randomizationHMG-CoA reductaseLipid-lowering drugPCSK9

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanProprotein Convertase 9PCSK9 InhibitorsCholesterol, LDLHydroxymethylglutaryl CoA Reductases

Autor:innen und Institutionen

  • Department of Cardiology, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
  • Department of Cardiology, First Affiliated Hospital of Lishui University School of Medicine, Lishui, China.

Zitieren

APA

Li, F., Mei, Y., Wu, Q., & Wu, X. (2024). Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation. Cardiology. https://doi.org/10.1159/000538551

Vancouver

Li F, Mei Y, Wu Q, Wu X. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation. Cardiology. 2024. doi:10.1159/000538551

BibTeX
@article{Li2024,
  author = {Li, Fuyuan and Mei, Yibin and Wu, Qiongbi and Wu, Xianjun},
  title = {Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation},
  journal = {Cardiology},
  year = {2024},
  doi = {10.1159/000538551}
}
Kostenlos starten →